SCHEDULE: Sio Capital Management Discloses 5.46% Stake in Aligos
Beneficial Ownership Disclosure
Sio Capital Management, LLC reported a 5.46% beneficial ownership stake in Aligos Therapeutics, Inc. as of December 31, 2025.
Summary
- Sio Capital Management, LLC beneficially owns 335,937 shares of Aligos Therapeutics, Inc. Common Stock.
- This ownership represents 5.46% of the outstanding Common Stock.
- The percentage is calculated based on 6,153,582 Common Shares outstanding as of October 31, 2025, as disclosed by Aligos Therapeutics' 10-Q on November 6, 2025.
- Sio Capital Management, LLC, a Delaware limited liability company, acts as a registered investment adviser to affiliated funds that hold these shares.
- Sio Capital Management, LLC has shared voting power and shared dispositive power over all 335,937 shares.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it simply discloses a significant passive ownership stake by an investment adviser, which can be seen as a vote of confidence.
Positives
- The disclosure of a 5.46% stake by Sio Capital Management, LLC indicates continued institutional interest in Aligos Therapeutics, Inc.
Future Outlook
NA
Management Comments
- Sio Capital Management, LLC certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that institutional filings like this provide transparency into significant ownership stakes, which can influence market perception of a company's stability and potential. For Aligos Therapeutics, the disclosure of Sio Capital Management's stake signals continued institutional interest in the biotechnology sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-10-31 | Date of outstanding shares calculation (6,153,582 Common Shares) used for percentage ownership. |
| 2025-12-31 | Date of the event which required the filing of this statement. |
| 2026-02-02 | Date the Schedule 13G was signed by Sio Capital Management, LLC. |
Keywords
Aligos Therapeutics, Sio Capital Management, Schedule 13G, beneficial ownership, investment adviser, common stock, institutional ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.